Three years of fighting against coronavirus disease

Three years ago, on March 11, 2020, the World Health Organization (WHO) declared a global pandemic due to the outbreak of the coronavirus infection.

Although COVID-19 is usually accompanied by mild symptoms, such as a dry cough, low-grade fever, anosmia, weakness and headache, sometimes serious complications like bacterial co-infections occur. Among them are bacterial pneumonia, sepsis and septic shock, that require antibiotic therapy.

Throughout this period, the pharmaceutical company Astrapharm has provided consumers with a sufficient quantity of drugs that are necessary for the effective treatment of upper and lower respiratory tract infections, primarily Azithromycin.

Azithromycin-Astrapharm is a representative of the group of macrolide antibiotics with a wide spectrum of antimicrobial action. It is included in the guidelines for the treatment of pneumonia and coronavirus disease (COVID-19) approved by the Ministry of Health of Ukraine.

Azithromycin mechanism of action including the inhibition of bacterial protein synthesis by binding to the 50S ribosomal subunit and prevention peptides` translocation without an influence on polynucleotide synthesis.

Azithromycin-Astrafarm is available in the form of capsules containing 500 mg of azithromycin, and it is recommended for adults and children whose body weight is more than 45 kg.

The product is prescribed by a doctor only and is available with a prescription.

Astrapharm – the art of helping people!